Disease Management References

Arnaldi G, Angeli AB, Atkinson X, Bertagna F, Cavagnini F, Chrousos GP et al. Diagnosis and complications of Cushing’s Syndrome: A consensus statement. J Clin Endocrinol Metab 2003; 88:5593–602.

Baudry C, Coste J, Bou Khalil R, et al. Efficiency and tolerance of mitotane in Cushing’s Disease in 76 patients from a single center. Eur J Endocrinol 2012; 167:473–81.

Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F, Fassnacht M, et al, on behalf of the ESMO Guidelines Working Group. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 31–138.

Berruti A, Grisanti , Pulzer A, Claps M, Daffara F, Loli P, et al. Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma. J Clin Endocrinol Metab 2017; 102:1358–65.

Castinetti F, Morange I, Jaquet P, Conte-Devoix B, Brue T. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing’s Disease. Eur J Endocrinol. 2008; 158:91–9.

Clayton RN, Jones PW, Reulen RC, Stewart PM, Hassan-Smith ZK, Ntali G et al. Mortality in patients with Cushing’s disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol 2016; 4:569–76.

Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, et al. A 12-month phase 3 study of pasireotide in Cushing’s Disease. N Engl J Med 2012; 366:914–24.

Corcuff JB, Young J, Masquefa-Giraud P, Chanson P, Blaudin E, Tabarin A. Rapid control of severe hypercortisolism with metyrapone ketoconazole. Eur J Endocrinol 2015; 172:473–81.

Cuevas-Ramos D, Lim DST, Fleseriu M. Update on medical treatment for Cushing’s Disease. Clin Diabetes Endocrinol 2016; 2:16.

Daniel E, Aylwin S, Mustafa O, Ball S, Munir A, Boelaert K, et al. Effectiveness of metyrapone in treating Cushing’s Syndrome a retrospective multicentre study in 195 patients. J Clin Endocrinol Metab 2015; 100:4146–54.

Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, Voormolen JH, et al. Mortality in patients treated for Cushing’s Disease is increased compared to patients treated for nonfunctioning pituitary macroadenomas. J Clin Endocrinol Metab 2007; 92:976–81.

Engelhardt D, Weber MM. Therapy of Cushing’s Syndrome with steroid biosynthesis inhibitors. J Steroid Biochem Mol Biol 1994; 49:261–7.

Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination Chemotherapy in Advanced Adrenocortical Carcinoma. N Engl J Med 2012; 366:2189–97.

Ferrau F and Korbonits M. Metabolic comorbidities in Cushing’s Syndrome. Eur J Endocrinol 2015; 173:M133–M157.

Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C; et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s Syndrome. J Clin Endocrinol Metab 2012; 97:2039–49.

Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A. Carbergoline monotherapy in the long-term treatment of Cushing’s Disease. Eur J Endocrinol 2010; 163:709–16.

Hassan-Smith ZK, Sherlock M, Reulen RC, Arlt W, Ayuk J, Toogood AA, et al. Outcome of Cushing’s Disease following transsphenoidal surgery in a single center over 20 years. J Clin Endocrinol Metab 2012; 97:1194–201.

Ketoconazole HRA 200mg Tablets Summary of Product Characteristics, updated 09-Mar-2017. HRA Pharma UK and Ireland Limited. Available from: https://www.medicines.org.uk/emc/medicine/30077 (accessed August 2017).

Morgan FH, Laufgraben M. Medical Management of Cushing’s Syndrome. Expert Rev Endocrinol Metab 2013; 8:183–93.

Newell-Price J, Petersenn S, Biller BMK, Roughton M, Ravichandran S, Lacroix A. Once-monthly injection of pasireotide LAR reduces urinary free cortisol (UFC) levels in patients with Cushing’s Disease: Results from a randomised, multicentre, phase III trial. Endocrine Abstracts 2016; 41:GP153.

Nieman LK, Biller BMK, Findling JW, Murad MH, Mewell-Price H, Savage MO, Tabarin A. Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100:2807–31.

Preda VA, Sen J, Karavitaki N, Grossman AB. Etomidate in the management of hypersortisolaemia in Cushing’s Syndrome: a review. Eur J Endocrinol 2012; 167:137–43.

Rizk A, Honegger J, Milian M, Psaras T. Treatment options in Cushing’s Disease. Clin Med Insights: Oncology 2012; 6:75–84.

Sharma ST, Nieman LK, Feelders RA. Cushing’s Syndrome: epidemiology and developments in disease management. Clinical Epidemiology 2015; 7:281–93.

Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LF, Grossman AB, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s Syndrome. Clin Endocrinol 1991; 35:169–78.

Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol 2009; 27:4619–29